On September 14, 2021, DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a public offering price of $17.00 per share. Wilson Sonsini Goodrich & Rosati advised DICE Therapeutics in IP matters related to the transaction.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by DICE, are expected to be $204 million. The shares began trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol “DICE.” BofA Securities, SVB Leerink, and Evercore ISI are acting as joint bookrunning managers for the offering.

The Wilson Sonsini patents and innovations team that advised DICE Therapeutics on IP matters related to the transaction was led by Julia Minitti and included Ying Chen, Luis Perla, and Mike Hostetler.

For more information, please see DICE Therapeutics’ press release.